About Us

Key strength: We have ready-to-go capacity to start from day 1 through our cultivation specialists. From scientific pharmaceutical cannabis cultivation, to R & D, production, manufacturing, extraction, wholesale, retail, training,R&D and laboratory.

OUR CORE PILLARS

  • Cultivation Process

    Cultivation

    Best practice, certified cultivation in Africa

  • Extraction

    Extraction

    We are in the process of funding a centralized extraction plant staffed with Chemical Engineers, Bio-chemocal engineers and scientists

  • Laboratory

    Laboratory

    Profiling of cannabinoids and terpenoids that fit medical conditions. Preventative, curative, management. Setting up of seed banks (Genetically modified and Crossbred chemovars)

  • Research & Development

    Research & Development

    We want the answers to medical conditions. The right drug to prevent, treat and manage medical conditions

  • Clinical trials

    Clinical trials

    We have experienced teams and ideal facilities for clinical trials

Our Competitive Advantage

1)      We have Demonstrated a growing concentration rate on our CBD product of 26.4% as opposed to the original content of CBD in cannabis S. 0.45%

This translates to 70% less in costs

  • Land
  • Water
  • Staff
  • Equipment

Or a 70% increase in profits – Better product at a lower price

 

2)      The merger of Clinical trials and the cannabis industry through our vast global scientific network and IP ensures our sustainable competitive advantage

3)      We have R&D licenses and are active in this area

4)      Clinical trials through our extensive in-house and partner labs

5)      We have medicinal cannabis licenses

6)      We have the right international GMP partners to get your business certified

7)      We have agreements with top companies in the industry and we can broker offtakes for your organisation.

 

Strong scientific approach and undertaken research from various departments. With numerous results from agronomy, biochemistry and clinical evaluation.

 

Ø  R & D has gained significant knowledge and IP in agronomy and medical science.

Cross breeding has resulted already in chemovars with an increased content of selected cannabinoids, increasing efficiency up to 70 times market standards

Significant in vitro, animal and observational research results creating the foundation for clinical trials and extended research efforts.

Creation of end users for buyers / pharmacies through the Pull strategy

Clinical Data0%
Research Data0%
Agronomy Data0%

Medical Cannabis in Africa - Roth Pharma | Medical Cannabiz Summit

Mission

BECOMING THE “GO TO #1” COMPANY FOR PHARMACEUTICAL GRADE CANNABIS IN AFRICA FOR PHARMACEUTICAL COMPANIES, BIOTECH COMPANIES AND RETAIL PHARMACIES GLOBALLY

We are positioning ourselves for complete vertical integration in Africa with a positioning focus on Pharmaceutical cannabis. This comprises of Licensing, Land acquisition, Cultivation, Staffing, Extraction, Distillation
Profiling of cannabinoids and terpenoids that fit medical conditions. Preventative , curative , management.
Focussed on  R&D Clinical Trials through our extensive in-house and partner labs.  Strong relations with universities globally.

Research and Development

We want the answers to medical conditions. The right drug to prevent, treat and manage medical conditions

 

TB

efficacy, accessibility and affordability with cannabis derivates in combination with two other substances, (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation. Conclusive Prelim Cell Invitro studies

Respiratory Infections

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, , physiological, pharmacokinetics, pharmacological and clinical evaluation.

Epilepsy

Refractory epilepsy (LGS) (SMEI-DS) efficacy, accessibility and affordability with cannabis derivates, (cannabinoid/terpenoid profile) evaluating bioavailability (liposome/nano). fMRI. Physiological, pharmacokinetics, pharmacological and clinical evaluation.

Alzheimer

efficacy, accessibility and affordability with cannabis derivates in combination with other substances, (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

Diabetes

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

Fibromyalgia

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

Cancer

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation. Positive conclusive Invitro studies..

Reproduction

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, , physiological, pharmacokinetics, pharmacological and clinical evaluation.

Malaria

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

HIV

efficacy, accessibility and affordability with cannabis derivates (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

Opioids

Focus on the effects of narcotics on physiological regulatory mechanisms of both the BTB and BBB, in particular, the effects of Cannabis, examining the effects of these narcotics on permeability across in vitro models of the BTB and BBB, rates of cell growth, morphology (HRSEM, HRTEM and fluorescence), viability, toxicology, mitochondrial function, apoptosis, ROS and ATP production, protein expression (PCR and Western blotting), etc., on the primary cellular components/cell lines of the BTB and BBB.

Patent Registration

Conclusive results have led to a ground breaking patent registration (Details under NDA)

Digital Pharma Leads

Roth Pharma is partnered with a US Pharma marketing company that specializes in prescription pain management and diabetes mainly. They own a chain of Pharmacies within the USA.

Roth Pharma have taken the gaming model of affiliate marketing and implemented into Pharmaceuticals. We have a network of affiliates supplying opt-in traffic in accordance with the HIIPPA legislation. Pharma companies can market specific products through us and we will generate privately insured patients to them. We have given pharmaceutical companies the ability to know exactly how many customers their dollars are buying and the ROI.

SEO

We currently have a strategic plan with a top-level SEO agency to develop content and SEO for the Pharma and Medical cannabis models that will generate opt-in patients.

LEADS

We have the ability to generate 300 Pharma leads per day that go through to our call center for triage and then directly on to our Teledoc partners for prescriptions. We deliver the medication to the patient and we provide refill management.

FUNNELS

We use full funnel conversion tactics to optimise Cost per patient. Outbound Calling and SMS are most successful.

Medical Cannabis

Combining cutting edge technology and science in the development of Medical Cannabis on an overall holistic approach. Depth of this is shown in the research information in this document.

We have ready-to-go capacity to start from day 1 through our cultivation specialists. From scientific medicinal cultivation, to R & D, production, manufacturing, wholesale, retail, training and laboratory.